European Advisory Group Backs Esperion's Cholesterol Drugs
The European Medicines Agency's (EMA) advisory group has voted in favor of approving two new cholesterol-lowering medicines developed by biopharmaceutical company Esperion Therepeutics (NASDAQ: ESPR). Following the positive opinion from the Committee for Medicinal Products for Human Use (CHMP), formal approval of bempedoic acid by the EMA is anticipated in April.
IMAGE SOURCE: GETTY IMAGES.
Bempedoic acid reduces the production of low-density lipoprotein cholesterol (LDL-C) in the body by targeting ATP citrate lyase (ACL), an enzyme that plays an important role in fatty acid biosynthesis.
Source Fool.com
